<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02184585</url>
  </required_header>
  <id_info>
    <org_study_id>117057</org_study_id>
    <nct_id>NCT02184585</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States</brief_title>
  <official_title>An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg Capsules and Tamsulosin Hydrochloride 0.2mg Tablets in Healthy Male Subjects in the Fed and Fasted States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label, randomized, single dose, three way crossover study in&#xD;
      healthy male subjects. The aim of the study is to evaluate the pharmacokinetic parameters of&#xD;
      two formulations of a fixed dose combination (FDC) capsule of dutasteride and tamsulosin&#xD;
      hydrochloride (HCl) (0.5 milligram [mg]/0.2 mg) relative to co-administration of dutasteride&#xD;
      0.5 mg capsules and tamsulosin hydrochloride 0.2 mg tablets in both the fed and fasted&#xD;
      states. Approximately 84 healthy adult male subjects will be enrolled into the study and&#xD;
      split into two cohorts (fed and fasted), allowing for approximately 36 subjects to complete&#xD;
      each cohort. Subjects from both cohorts will receive single oral doses in 3 treatment periods&#xD;
      and be randomized to one of six different treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA)&#xD;
      wherein A= FDC1: Dutasteride and tamsulosin HCl (0.5 mg/0.2 mg), B= FDC2: Dutasteride and&#xD;
      tamsulosin HCl (0.5 mg/0.2 mg), C= Co-administration of commercial formulations of&#xD;
      dutasteride(0.5mg) and tamsulosin HCl (0.2mg). Each treatment period will be separated by a&#xD;
      minimum 28 day washout period. Blood samples for pharmacokinetic analysis will be taken at&#xD;
      regular intervals after dosing. Safety will be assessed by measurement of blood pressure,&#xD;
      heart rate and review of adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2014</start_date>
  <completion_date type="Actual">February 23, 2015</completion_date>
  <primary_completion_date type="Actual">February 23, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from 0 to the time of the last quantifiable concentration (AUC[0-t]) of tamsulosin in serum</measure>
    <time_frame>Pre-dose and post dose at 15 minutes (min), 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hours (h).</time_frame>
    <description>Relative bioavailability of tamsulosin will be assessed by evaluating AUC (0-t).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from 0 to infinity (AUC[0-infinity]) of tamsulosin in serum</measure>
    <time_frame>Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose.</time_frame>
    <description>Relative bioavailability of tamsulosin will be assessed by evaluating AUC (0-infinity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax) of dutasteride in serum</measure>
    <time_frame>Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose.</time_frame>
    <description>Relative bioavailability of dutasteride will be assessed by evaluating Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) of dutasteride in serum</measure>
    <time_frame>Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose.</time_frame>
    <description>Relative bioavailability of dutasteride will be assessed by evaluating AUC(0-t)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum serum concentration (tmax) of tamsulosin and dutasteride in serum</measure>
    <time_frame>Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose</time_frame>
    <description>Pharmacokinetics of dutasteride and tamsulosin will be characterised by measuring tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t½) of tamsulosin in serum (as data permit).</measure>
    <time_frame>Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose</time_frame>
    <description>Pharmacokinetics of dutasteride and tamsulosin will be characterised by measuring t½</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by Vital signs (blood pressure and pulse rate [PR])</measure>
    <time_frame>Up to Day 110</time_frame>
    <description>Vital sign measurements will be measured in supine position after 5 minutes rest and will include systolic and diastolic blood pressure and pulse rate. Baseline for vital signs will be defined as the mean of the two blood pressure and pulse readings on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by electrocardiogram (ECG) measurements</measure>
    <time_frame>Up to Day 110</time_frame>
    <description>Single 12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Baseline for ECG will be defined as the mean of three measurements on Day -1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by review of adverse events (AEs)</measure>
    <time_frame>Up to Day 110</time_frame>
    <description>AEs will be collected from the start of dosing with Investigational Product and until the follow-up visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by clinical laboratory safety data</measure>
    <time_frame>Up to Day 56</time_frame>
    <description>Clinical laboratory tests will include hematology, clinical chemistry and urinalysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Fasted state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 : Fed state</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment sequence A</intervention_name>
    <description>FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.</description>
    <arm_group_label>Cohort 1: Fasted state</arm_group_label>
    <arm_group_label>Cohort 2 : Fed state</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment sequence B</intervention_name>
    <description>FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.</description>
    <arm_group_label>Cohort 1: Fasted state</arm_group_label>
    <arm_group_label>Cohort 2 : Fed state</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment sequence C</intervention_name>
    <description>Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).</description>
    <arm_group_label>Cohort 1: Fasted state</arm_group_label>
    <arm_group_label>Cohort 2 : Fed state</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males aged between 18 and 65 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s)&#xD;
             which is/are not specifically listed in the inclusion or exclusion criteria, outside&#xD;
             the reference range for the population being studied may be included only if the&#xD;
             Investigator, in consultation with the GSK Medical Monitor if required, agree and&#xD;
             document that the finding is unlikely to introduce additional risk factors and will&#xD;
             not interfere with the study procedures.&#xD;
&#xD;
          -  Body weight &gt;=50 kilogram (kg) and body mass index (BMI) within the range 18 - 32&#xD;
             kg/m^2 (square meter) (inclusive).&#xD;
&#xD;
          -  Male subjects with female partners of child-bearing potential must agree to use a&#xD;
             condom. This criterion must be followed from the time of the first dose of study&#xD;
             medication until 50 days post-last dose.&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) &lt;2x (Upper limit&#xD;
             of normal) ULN; alkaline phosphatase and bilirubin &lt;=1.5xULN (isolated bilirubin&#xD;
             &gt;1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Based on single or averaged corrected QT (QTc) values of triplicate electrocardiograms&#xD;
             (ECGs) obtained over a brief recording period: QT duration corrected for heart rate by&#xD;
             Fridericia's formula (QTcF) &lt;450 milliseconds (msec)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria Based Upon Medical Histories&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or&#xD;
             GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal&#xD;
             reactions or any other signs and symptoms of orthostasis, which in the opinion of the&#xD;
             investigator could be exacerbated by tamsulosin and result in putting the subject at&#xD;
             risk of injury.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined for US&#xD;
             sites as: an average weekly intake of &gt;14 drinks for males or &gt;7 drinks for females.&#xD;
             One drink is equivalent to 12 gram (g) of alcohol: 12 ounces (360 millilitre [mL]) of&#xD;
             beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.&#xD;
&#xD;
          -  History of diabetes or peptic ulcer disease which is uncontrolled by medical&#xD;
             management.&#xD;
&#xD;
          -  History of breast cancer or clinical breast examination finding suggestive of&#xD;
             malignancy. History of malignancy within the past five years, except for basal cell&#xD;
             carcinoma of the skin. Subjects with a prior malignancy who have had no evidence of&#xD;
             disease for at least the past 5 years are eligible.&#xD;
&#xD;
          -  Prior medical history or evidence of prostate cancer (e.g., positive biopsy, or&#xD;
             suspicious ultrasound, or suspicious digital rectal examination [DRE]). Patients with&#xD;
             suspicious ultrasound or DRE who have had a negative biopsy within the preceding 6&#xD;
             months and stable prostate specific antigen (PSA) are eligible for the study. Note:&#xD;
             The investigator should make every appropriate effort to exclude the possibility of&#xD;
             prostate cancer, including consideration of prostate biopsy in any subject with a&#xD;
             known abnormal PSA.&#xD;
&#xD;
        Criteria Based Upon Diagnostic Assessments&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening;&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive test for Human Immunodeficiency Virus (HIV) antibody. Other Criteria&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Unable to refrain from the use of prescription or non-prescription drugs, including&#xD;
             vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or&#xD;
             14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is&#xD;
             longer) prior to the first dose of study medication, unless in the opinion of the&#xD;
             Investigator and GSK Medical Monitor the medication will not interfere with the study&#xD;
             procedures or compromise subject safety.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>June 18, 2018</last_update_submitted>
  <last_update_submitted_qc>June 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioavailability</keyword>
  <keyword>crossover design</keyword>
  <keyword>healthy male volunteers</keyword>
  <keyword>tamsulosin hydrochloride</keyword>
  <keyword>Dutasteride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>117057</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>117057</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>117057</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>117057</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>117057</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>117057</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>117057</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02184585
org study id: 117057
nct id: NCT02184585
lead sponsor: 
has dmc: No
This study will be an open-label, randomized, single dose, three way crossover study in
      healthy male subjects. The aim of the study is to evaluate the pharmacokinetic parameters of
      two formulations of a fixed dose combination (FDC) capsule of dutasteride and tamsulosin
      hydrochloride (HCl) (0.5 milligram [mg]/0.2 mg) relative to co-administration of dutasteride
      0.5 mg capsules and tamsulosin hydrochloride 0.2 mg tablets in both the fed and fasted
      states. Approximately 84 healthy adult male subjects will be enrolled into the study and
      split into two cohorts (fed and fasted), allowing for approximately 36 subjects to complete
      each cohort. Subjects from both cohorts will receive single oral doses in 3 treatment periods
      and be randomized to one of six different treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA)
      wherein A= FDC1: Dutasteride and tamsulosin HCl (0.5 mg/0.2 mg), B= FDC2: Dutasteride and
      tamsulosin HCl (0.5 mg/0.2 mg), C= Co-administration of commercial formulations of
      dutasteride(0.5mg) and tamsulosin HCl (0.2mg). Each treatment period will be separated by a
      minimum 28 day washout period. Blood samples for pharmacokinetic analysis will be taken at
      regular intervals after dosing. Safety will be assessed by measurement of blood pressure,
      heart rate and review of adverse events.
allocation: Randomized
intervention model: Crossover Assignment
primary purpose: Other
masking: None (Open Label)
measure: Area under the curve from 0 to the time of the last quantifiable concentration (AUC[0-t]) of tamsulosin in serum
time frame: Pre-dose and post dose at 15 minutes (min), 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 hours (h).
description: Relative bioavailability of tamsulosin will be assessed by evaluating AUC (0-t).
measure: Area under the curve from 0 to infinity (AUC[0-infinity]) of tamsulosin in serum
time frame: Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose.
description: Relative bioavailability of tamsulosin will be assessed by evaluating AUC (0-infinity).
measure: Maximum drug concentration (Cmax) of dutasteride in serum
time frame: Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose.
description: Relative bioavailability of dutasteride will be assessed by evaluating Cmax
measure: AUC(0-t) of dutasteride in serum
time frame: Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose.
description: Relative bioavailability of dutasteride will be assessed by evaluating AUC(0-t)
measure: Time to reach maximum serum concentration (tmax) of tamsulosin and dutasteride in serum
time frame: Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose
description: Pharmacokinetics of dutasteride and tamsulosin will be characterised by measuring tmax.
measure: Terminal half-life (t½) of tamsulosin in serum (as data permit).
time frame: Pre-dose and post dose at 15 min, 30 min, 45 min, 1, 1.5, 2, 3, 6, 8, 10, 12, 18, 24, 36, 48 and 72 h post dose
description: Pharmacokinetics of dutasteride and tamsulosin will be characterised by measuring t½
measure: Safety and tolerability as assessed by Vital signs (blood pressure and pulse rate [PR])
time frame: Up to Day 110
description: Vital sign measurements will be measured in supine position after 5 minutes rest and will include systolic and diastolic blood pressure and pulse rate. Baseline for vital signs will be defined as the mean of the two blood pressure and pulse readings on Day -1.
measure: Safety and tolerability as assessed by electrocardiogram (ECG) measurements
time frame: Up to Day 110
description: Single 12-lead ECGs will be obtained at each time point during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Baseline for ECG will be defined as the mean of three measurements on Day -1
measure: Safety and tolerability as assessed by review of adverse events (AEs)
time frame: Up to Day 110
description: AEs will be collected from the start of dosing with Investigational Product and until the follow-up visit
measure: Safety and tolerability as assessed by clinical laboratory safety data
time frame: Up to Day 56
description: Clinical laboratory tests will include hematology, clinical chemistry and urinalysis
arm group label: Cohort 1: Fasted state
arm group type: Experimental
description: Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
arm group label: Cohort 2 : Fed state
arm group type: Experimental
description: Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
intervention type: Drug
intervention name: Treatment sequence A
description: FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
arm group label: Cohort 1: Fasted state
arm group label: Cohort 2 : Fed state
intervention type: Drug
intervention name: Treatment sequence B
description: FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
arm group label: Cohort 1: Fasted state
arm group label: Cohort 2 : Fed state
intervention type: Drug
intervention name: Treatment sequence C
description: Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
arm group label: Cohort 1: Fasted state
arm group label: Cohort 2 : Fed state
criteria: 
gender: Male
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
last name: GSK Clinical Trials
role: Study Director
affiliation: GlaxoSmithKline
facility: 
country: United States
responsible party type: Sponsor
mesh term: Prostatic Hyperplasia
mesh term: Hyperplasia
sharing ipd: Yes
ipd description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 
study doc: 